Ord rates MA Financial (ASX:MAF) as a buy with a boosted price target of $10.50. The company is currently enjoying strong operating momentum, with three upgrades to earnings guidance over the last six months.Additionally, the financial group is a key beneficiary of the re-opening theme and Ords expect ongoing growth in asset management, long term optionality in lending and a steady contribution from corporate advisory. The target price got a boost by 90 per cent from $5.53 to $10.50.
- Forums
- ASX - By Stock
- MAF
- Ann: MAF Earnings Guidance Upgrade and Business Update
Ann: MAF Earnings Guidance Upgrade and Business Update, page-4
Featured News
Add MAF (ASX) to my watchlist
|
|||||
Last
$4.35 |
Change
-0.020(0.46%) |
Mkt cap ! $788.8M |
Open | High | Low | Value | Volume |
$4.44 | $4.48 | $4.35 | $958.8K | 217.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1683 | $4.34 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.38 | 422 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1683 | 4.340 |
2 | 1953 | 4.330 |
2 | 1940 | 4.320 |
2 | 4342 | 4.310 |
1 | 2400 | 4.280 |
Price($) | Vol. | No. |
---|---|---|
4.380 | 422 | 1 |
4.390 | 1096 | 1 |
4.400 | 1096 | 1 |
4.450 | 7785 | 1 |
4.510 | 5000 | 1 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
MAF (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online